Akdeniz, SHarman, MAtmaca, SYaldiz, M2024-04-242024-04-2420051368-50311742-1241https://doi.org/10.1111/j.1742-1241.2005.00589.xhttps://hdl.handle.net/11468/17651The aim of this study is to evaluate the efficiency of low-dose, low-molecular-weight heparin (enoxaparin) in the treatment of lichen planus (LP). Twenty-four patients clinically and histopathologically diagnosed as LP with intense pruritus were treated with 3 mg of enoxaparin (Clexane((R))), subcutaneously once a week for 4-14 weeks. Complete remission was observed in 20 of 24 patients (83%) who had widespread cutaneous involvement, but no or minimal effect was observed in four of 24 patients, three of whom had chronic hypertrophic LP. Low-dose enoxaparin was observed to be effective in the treatment of LP without any side-effects. Enoxaparin may be an effective and simple alternative therapy for LP.eninfo:eu-repo/semantics/openAccessLichen PlanusLow-Molecular-Weight HeparinArticle591112681271WOS:0002326582000072-s2.0-336448749901623607810.1111/j.1742-1241.2005.00589.xQ1Q2